Barclays PLC Buys 30,990 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL)

Barclays PLC lifted its stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) by 130.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 54,810 shares of the company’s stock after acquiring an additional 30,990 shares during the period. Barclays PLC owned approximately 0.12% of Werewolf Therapeutics worth $116,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in HOWL. Millennium Management LLC boosted its holdings in shares of Werewolf Therapeutics by 96.4% in the second quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock worth $2,709,000 after acquiring an additional 544,881 shares during the period. PFM Health Sciences LP boosted its holdings in shares of Werewolf Therapeutics by 4.9% in the third quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock worth $7,205,000 after acquiring an additional 157,673 shares during the period. Marshall Wace LLP boosted its holdings in shares of Werewolf Therapeutics by 410.5% in the second quarter. Marshall Wace LLP now owns 134,184 shares of the company’s stock worth $327,000 after acquiring an additional 107,900 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Werewolf Therapeutics by 103.1% in the second quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock worth $417,000 after acquiring an additional 86,800 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in shares of Werewolf Therapeutics in the second quarter worth $165,000. 64.84% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a report on Tuesday, November 19th.

Werewolf Therapeutics Price Performance

NASDAQ:HOWL opened at $1.44 on Thursday. The firm has a market capitalization of $64.17 million, a price-to-earnings ratio of -0.94 and a beta of 0.38. Werewolf Therapeutics, Inc. has a 52-week low of $1.38 and a 52-week high of $8.19. The stock has a fifty day moving average of $1.83 and a 200 day moving average of $2.14. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.